The Bladder Cancer Index (BCI) was developed by researchers at the University of Michigan to measure health related quality of life among men with bladder cancer. It represents an adaptation of the UCLA Prostate Cancer Index, modified to enhance sensitivity to therapy effects by increasing the number of prostate-targeted items to 50 (compared to 20 in the original UCLA-PCI). EPIC has been validated in men with localized prostate cancer who underwent surgery, external beam radiation, or brachytherapy with or without the use of hormonal adjuvants. EPIC is sensitive to specific HRQOL effects of these therapies and to HRQOL effects of cancer progression.
Bladder Cancer Index Questionnaire